TIOTROPIUM BROMIDE IN THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A RECIPE FOR SUCCESS
https://doi.org/10.18093/0869-0189-2011-0-1-100-106
Abstract
Tiotropium bromide in therapy of chronic obstructive pulmonary disease: a recipe for success
About the Author
S. N. Avdeev
ФГУ "НИИ пульмонологии" ФМБА России
Russian Federation
Russian Federation
д. м. н., проф., руководитель клинического отдела
105077, Москва, ул. 116я Парковая, 32, к. 4.
Тел: (495) 465-53-64.
References
1. Global Initiative for Chronic Obstructive Lung Diseas(GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease.NHLBI / WHO workshop report. The 2009 report is available on www.goldcopd.com
2. Buist A.S., McBurnie M.A., Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a population based prevalence study. Lancet 2007; 370:741–750.
3. Чучалин А.Г., Овчаренко С.И., Лещенко И.В., Белевский А.С. Определение, классификация и диагностика ХОБЛ. В кн.: Чучалин А.Г. (ред.). Клинические рекомендации. Хроническая обструктивная болезнь легких. М.: Атмосфера, 2007. 8–22.
4. Celli B.R., MacNee W., ATS / ERS Task Force. Standards for the diagnosis and treatment of patients with COPD:a summary of the ATS / ERS position paper. Eur. Respir. J.2004; 23: 932–946.
5. Panning C.A., DeBisschop M. Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy 2003; 23: 183–189.
6. Tashkin D.P. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr.Opin. Pulm. Med. 2010; 16: 97–105.
7. Donohue J.F., van Noord J.A., Bateman E.D. et al. A 6-month,placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47–55.
8. Celli B., Wallack R.Z., Wang S. et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743–1748.
9. Cazzola M., Matera M.G. Emerging inhaled bronchodilators: an update. Eur. Respir. J. 2009; 34: 757–769.
10. Bauwens O., Ninane V., Van de Maele B. et al. 24-hour bronchodilator efficacy of single doses indacaterol in subjects with COPD: comparison with placebo and formoterol.Curr. Med. Res. Opin. 2009; 25: 463–470.
11. Beier J., Beeh K.M., Brookman L. et al. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm. Pharmacol. Ther. 2009; 22 (6): 492–496.
12. Fogarty C., Worth H., Hebert J. et al. Sustained 24-h bronchodilation with indacaterol once-daily in COPD: a 26-week efficacy and safety study. Am. J. Respir. Crit. Care Med.2009; 179: A4547.
13. Magnussen H., Paggiaro P., Jack D. et al. Bronchodilatador treatment with indacaterol once daily vs formoterol twicedaily in COPD: a 52 week study. Am. J. Respir. Crit. Care Med. 2009; 179: A6184.
14. Nonikov V., Verkindre C., Jack D. et al. Indacaterol once-daily reduces days of poor control in COPD over 52 weeks of treatment. Am. J. Respir. Crit. Care Med. 2009; 179: A6190.
15. Magnussen H., Paggiaro P., Jack D. et al. Indacaterol once-daily improves health related quality of life in COPD patients: a 52-week study versus placebo and formoterol.Eur. Respir. J. 2009; 53s: P2019.
16. Buhl R., Pieters W., Jack D. et al. Indacaterol once-daily improves dyspnoea and BODE index in COPD patients: a 52-week study versus twice daily formoterol. Eur. Respir.J. 2009; 53s: P2026.
17. Buhl R., Pieters W., Jack D. et al. Indacaterol once-daily reduces COPD exacerbations over 52 weeks of treatment.Am. J. Respir. Crit. Care Med. 2009; 179: A6185.
18. Worth H., Kleerup E., Iqbal A. et al. Safety and tolerability of indacaterol once daily in COPD patients versus placebo and tiotropium: a 26 week study. Eur. Respir. J. 2009; 53s:P2030.
19. Chung F., Kornmann O., Jack D. et al. Safety and tolerability of indacaterol over 52 weeks of treatment in COPD. Eur.Respir. J. 2009; 53s: E4359.
20. Fletcher C.M., Elmes P.C., Wood C.H. The significance of respiratory symptoms and the diagnosis of chromic bronchitis in a working population. Br. Med. J. 1959; 1: 257–266.
21. Kohansal R., Martinez%Camblor P., Agusti A. et al. The natural history of chronic airflow obstruction revisited: an analysis of the framingham offspring cohort. Am. J. Respir. Crit.Care Med. 2009; 180: 3–10.
22. Decramer M., Celli B., Tashkin D.P. et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the Uplift trial. COPD 2004; 1: 303–312.
23. Scanlon P.D., Connett J.E., Waller L.A. et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: the Lung Health Study.Am. J. Respir. Crit. Care Med. 2000; 161: 381–390.
24. Anthonisen N.R., Skeans M.A.,Wise R.A. et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142:233–239.
25. Tashkin D.P., Celli B., Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl.J. Med. 2008; 359: 1543–1554.
26. Vincken W., van Noord J.A., Greefhorst A.P.M. et al.Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19:209–216.
27. Anzueto A., Tashkin D., Menjoge S., Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm. Pharmacol. Ther.2005; 18: 75–81.
28. Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N. Engl. J. Med. 1999; 340: 1948–1953.
29. Vestbo J., Sorensen T., Lange P. et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial.Lancet 1999; 353: 1819–1823.
30. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med.2000; 343: 1902–1909.
31. Burge P.S., Calverley P.M.A., Jones P.W. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000;320: 1297–1303.
32. Decramer M., Rutten%van Molken M., Dekhuijzen P.N. et al.Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005; 365: 1552–1560.
33. Calverley P., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of COPD: a randomized controlled trial. Lancet 2003; 361 (9356): 449–456.
34. Decramer M., Celli B., Kesten S. et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374:1171–1178.
35. Troosters T., Celli B., Lystig T. et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur. Respir. J. 2010; 36: 65–73.
36. Morice A.H., Celli B., Kesten S. et al. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir. Med. 2010; 104: 1659–1667.
37. Murray C.J.L., Lopez A.D. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269–1276.
38. Mannino D.M., Homa D.M., Akinbami L.J. et al. Chronic obstructive pulmonary disease surveillance – United States,1971–2000. Morbid. Mortal. Wkly Rep. Surveill. Summ.2002; 51: 1–16.
39. World Health Organization. Global initiative for chronic obstructive lung disease. Geneva (Switzerland): World Health Organization; 2002.
40. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681–686.
41. Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann. Intern. Med. 1980; 93:391–398.
42. Anthonisen N.R., Skeans M.A.,Wise R.A. et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142:233–239.
43. National Emphysema Treatment Trial Research Group.A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N. Engl.J. Med. 2003; 348: 2059–2073.
44. Lightowler J.V., Wedzicha J.A., Elliott M.W., Ram F.S.Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. Br. Med. J. 2003; 326: 185–189.
45. Salpeter S.R., Buckley N.S., Salpeter E.E. Meta-analysis: Anticholinergics, but not β-agonists, reduce severe exacerbations and respiratory mortality in COPD. J. Gen. Intern.Med. 2006; 21: 1011–1019.
46. De Luise C., Lanes S.F., Jacobsen J. et al. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur. J. Epidemiol. 2007; 22:267–272.
47. Hansell A.L., Walk J.A., Soriano J.B. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur. Respir. J. 2003; 22: 809–814.
48. Camilli A.E., Robbins D.R., Lebowitz M.D. Death certificate reporting of confirmed airways obstructive disease. Am. J.Epidemiol. 1991; 133: 795–800.
49. Engstrom G., Wollmer P., Hedblad B. et al. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from "men born in 1914",Malmo, Sweden. Circulation 2001; 103: 3086–3091.
50. Huiart L., Ernst P., Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005; 128: 26400–2646.
51. Viegas C.A., Ferrer A., Montserrat J.M. Ventilation-perfusionresponse after fenoterol in hypoxemic patients with stable COPD. Chest 1996; 110: 71–77.
52. Singh S., Loke Y.K., Furberg C.D. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis. J.A.M.A. 2008; 300: 1439–1450.
53. Celli B., Decramer M., Leimer I. et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137;20–30.
54. Reilly J.J. COPD and declining FEV1 – time to divide and conquer? N. Engl. J. Med. 2008; 359: 1616–1618.
55. Burrows B., Fletcher C.M., Heard B.E. et al. The emphysematous and bronchial types of chronic airways obstruction.A clinicopathological study of patients in London and Chicago. Lancet 1966; 87: 830–835.
56. Garcia-Aymerich J., Agusti А., Barberа J.A. et al. Phenotypic heterogeneity of chronic obstructive pulmonary disease.Arch. Bronconeumol. 2009; 45: 133–142.
57. Han M.K., Agusti A., Calverley P.M. et al. COPD phenotypes: The future of COPD. Am. J. Respir. Crit. Care Med.2010; 182: 598–604.
58. Lee J.-H., Lee Y.K., Kim E.-K. et al. Responses to inhaled Long-acting beta-agonist and corticosteroid according to COPD subtype. Respir. Med. 2010; 104: 542–549.
59. Gelb A.F., Taylor C.F., Cassino C. et al. Tiotropium induced bronchodilation and protection from dynamic hyperinflation is independent of extent of emphysema in COPD.Pulm. Pharmacol. Ther. 2009; 22: 237–242.
60. Tashkin D.P., Celli B., Kesten S. et al. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur. Respir. J. 2010; 35: 287–294.
61. Tashkin D.P., Celli B., Kesten S. et al. Effect of tiotropium in men and women with COPD: Results of the 4-year UPLIFT trial. Respir. Med. 2010; 104: 1495–1504.
Review
For citations:
Avdeev S.N. TIOTROPIUM BROMIDE IN THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A RECIPE FOR SUCCESS. PULMONOLOGIYA. 2011;(1):100-106. (In Russ.) https://doi.org/10.18093/0869-0189-2011-0-1-100-106
Views:
907
Email this article 